HK Stock Market Move | LIFETECH SCI (01302) rose more than 8% in morning trading; the IBS coronary stent has obtained EU CE MDR certification.

LIFETECH SCI (01302) rose more than 8% in morning trading. As of press time, it was up 4.76% at HK$1.54, with a turnover of HK$34.4871 million. On the news front, LIFETECH SCI announced that the IBS bioabsorbable drug-eluting coronary stent system independently developed by its subsidiary Yuanxin Technology (Shenzhen) Co., Ltd. has obtained EU CE MDR certification. The product is the world's first iron-based coronary stent system to receive marketing approval. The series of clinical studies on the IBS coronary stent provide solid evidence-based support for the success of its global commercialization. Following CE approval of this product, a large randomized controlled post-market study with TLF as the primary endpoint will begin in Europe to further enrich the clinical evidence for this product.